Old Pill, New Win Against Crippling Fatigue

Man with headache holding a glass of water — Photo: fizkes / Shutterstock

A cheap, old antidepressant just became one of the first drugs to clearly dent long COVID’s crushing fatigue — and the effect did not vanish when the pills stopped.

Story Snapshot

Fluvoxamine, a common antidepressant, cut long COVID fatigue more than placebo in a major trial
Benefits were still present 30 days after patients stopped taking the drug
Quality of life improved, and serious side effects were rare
Experts call it “encouraging” but stress it is not yet a standard long COVID cure

A long-awaited win against long COVID fatigue

Doctors enrolled 399 adults who still had heavy fatigue at least 90 days after a confirmed COVID infection. These people were not just “a little tired.” Many could not work full days, care for family, or live the lives they had before the virus. In the trial, patients were randomly given fluvoxamine, metformin, or a fake pill for 60 days, so no one knew who was on the real drug until the study ended.

Fluvoxamine was given at 100 milligrams twice a day, a dose already used for depression and anxiety. Fatigue was measured with a standard tool called the Fatigue Severity Scale, where small changes can still matter in daily life. By day 60, people on fluvoxamine had fatigue scores about 0.43 points lower than those on placebo, and by day 90 the difference grew to about 0.58 points. For a group stuck in long-term exhaustion, that shift is not trivial.

How strong was the signal, really?

The trial team used a modern, Bayesian way of checking the data, which asks “how likely is it that the drug beats placebo?” not just “is it yes or no?” They reported about a 99 percent probability that fluvoxamine outperformed placebo for fatigue reduction. An independent board even stopped the fluvoxamine arm early for benefit, because the advantage was clear enough they no longer needed to keep randomizing new patients to placebo. That kind of early stop for success is rare in this space.

Improvements were not just numbers on a chart. People on fluvoxamine were more likely to rate their fatigue in the “milder” range of the seven-point scale, and more of them said they felt meaningfully better by day 60. They also reported better scores on quality-of-life measures, including daily function and well-being. News outlets covering the study called it one of the first real treatment wins for long COVID fatigue, a label long COVID patients have waited years to see.

Safety, side effects, and what did not work

Many readers will ask a simple question: does the drug do harm while it does good? In this trial, adverse events were actually less common in the fluvoxamine group than in the metformin or placebo groups, and serious events were rare across all groups. That does not mean the drug is risk-free. Fluvoxamine can interact with other medicines and can cause nausea, sleep changes, or mood shifts. But the study did not show any new, worrying safety signal in this long COVID population.

Metformin, a low-cost diabetes drug, was tested in the same study, but its story was different. It showed a modest drop in fatigue at 30 days, then lost that edge by later time points. In short, metformin did not provide sustained benefit for long COVID fatigue in this trial, while fluvoxamine did. That contrast matters for patients who hear social media buzz about “cheap fixes.” Not every repurposed drug pans out once it faces real randomized data.

Why might an antidepressant ease viral fatigue?

Fluvoxamine is best known as a selective serotonin reuptake inhibitor, used for depression and obsessive-compulsive disorder. But researchers suspect other actions matter here. Lab and early clinical work suggests it affects inflammation and cell stress pathways tied to COVID and its after-effects. One randomized trial during acute infection found fewer later fatigue complaints in people who took fluvoxamine while sick, hinting at both treatment and prevention roles for post-COVID fatigue.

Scientists argue that the drug’s impact on immune signaling and cell stress could explain why fatigue shifts even in patients without major depression. If the problem is partly biological damage from infection, then a drug that calms those pathways may help, even if it was first approved for mood. At the same time, this does not prove all antidepressants will help long COVID, and responsible doctors will avoid overpromising until more trials report.

What this means for patients and policy right now

Experts praising the study still urge caution. One adviser from a long COVID charity noted that some people improve over time on their own, so any drug result must be weighed against natural recovery. Larger, multi-country phase three trials, like the REVITALIZE platform, are now being built to confirm if fluvoxamine’s benefit holds in broader and more diverse groups. So far, no national guideline has declared fluvoxamine a standard, first-line treatment for long COVID fatigue.

Still, for millions living with long COVID, this trial breaks an important psychological barrier. Until now, most studies showed tiny short-term gains that faded fast or failed to matter in real life. Here, a familiar, inexpensive drug gave sustained relief over three months, with a very high chance the effect was real, not random. For middle-aged readers weighing personal risk and freedom, the message is clear: long COVID is not “all in your head,” and targeted drugs may finally be starting to chip away at its most disabling symptom.